Convalescent plasma is a promising therapeutic strategy that might have benefit in patients with COVID-19, 1, 2 despite unproven safety and efficacy. Although randomised clinical trials are ongoing, decision making with regard to the transfusion of convalescent plasma from patients who have recovered from COVID-19should follow a risk-based approach, whereby the potential risks are minimised in favour of not yet proven therapeutic benefits. WHO Blood Regulators Network and several other stakeholders, such as the International Society of Blood Transfusion, recommend risk mitigation for transfusion-transmissible disease through pathogen inactivation. 3, 4 However, at present no data exist regarding the effect of pathogen-inactivation methods or cryopreservation on the stability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibodies.